HANSOH PHARMA (03692) has announced that the New Drug Application for its innovative product, the Olepeptide Injection, has been accepted for review by China's National Medical Products Administration.
The application was formally accepted on June 3, 2026. The drug is intended for the long-term weight management of adults who are obese or overweight.
Olepeptide is a novel, once-weekly dual agonist targeting both the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors. It is a proprietary drug candidate developed independently by the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments